Tirizepatidi(GLP-2) miligaramu 30

▎ Tirzepatide (Tirzepatide) ka baarakɛcogo

▎ Tirzepatidi ɲinini

Tirzepatide ka ɲininiw kɛcogo ye mun ye?

Tirzepatide ka ɲininiw kɛcogo bɔra fɔlɔ farikoloɲɛnajɛ furakɛli furaw ɲinini na ani farikolojidɛsɛ furaw ɲinini na. Laadalata farikolojɔli furaw dan ye, ka sɔrɔ GLP-1 minɛbagaw bɛ se ka joli sukaro kunbɛnni ɲɛ, o bɛ ɲininikɛlaw bila ka fura nafama caman dilan minnu bɛ sɔrɔ o suguya kelen na. I n’a fɔ GIP/GLP-1 dual receptor agoniste, Tirzepatide bɛ se ka joli sukaro hakɛ labɛn ka ɲɛ. Diɲɛ kɔnɔ, mɔgɔ minnu girinya ka ca ani minnu fasalen don, olu cayara, o kɛra sababu ye ka farikolo girinya kunbɛnni kɛ kɛnɛyaso mago kɔrɔtɔlen ye. GLP-1 minɛbaga agonistew bɛ mɔgɔ farikolo girinya dɔgɔya, o b’a to u bɛ kɛ mɔgɔ girinya dɔgɔyali laɲini ye. Tirizepatidi ye mɔgɔw hakili sama ka da a ka girinya dɔgɔyali kɔlɔlɔ ɲumanw kan.

Tirzepatide ka baara kɛcogo ye mun ye?

Agonisɛri min bɛ kɛ ni recepteur fila ye: 

Tirzepatidi ye pepitiri-1 (GLP-1) ye min bɛ i n’a fɔ glukagon fila ani glucose-dependent insulinotropic polypeptide (GIP) minɛbaga [1,2](Wong E, 2023; Kumar D, 2022). GLP-1 ni GIP fila bɛɛ ye inkretini ɔrimɔni ye minnu bɛ sɔrɔ banakɔtaa la, u jɔyɔrɔ ka bon sukaro homeostasis sabatili la. Tirzepatide bɛ jɛɲɔgɔnya kɛ ni GLP-1 ni GIP minɛbagaw baara ye waati kelen na, o la, a bɛ joli sukaro hakɛ labɛn.

Insuline ni glucagon bɔli ɲɛnabɔli: 

A bɛ dɔ fara inisɔndiya sɔrɔli ni a bɔli kan ka sɔrɔ ka sukaro bɔli dɔgɔya cogo la min bɛ tali kɛ sukaro la. Ni sukaro hakɛ cayara joli la, Tirzepatide bɛ pankreyasi β-cellw lawuli u ka inisɔndiya bɔ, o bɛ sukaro tali ni a baara sabati, o bɛ sukaro hakɛ dɔgɔya joli la o waati kelen na, a bɛ pankreyasi α-cellw bali ka sukaro bɔ, ka sugunɛ sukaro bɔli dɔgɔya, ka joli sukaro hakɛ dɔgɔya ka taa a fɛ, ani ka joli sukaro hakɛ kɔlɔsi kosɛbɛ sunɔgɔ ni dumuni kɔfɛ ^[1,.

Waleya kɛcogo wɛrɛw: 

Tirizepatidi fana bɛ fasa sabati, o bɛ se ka kɛ sababu ye ka GLP-1 minɛbagaw baara, ka baara kɛ farikolo cɛmancɛ la, ani ka nɔ bila dumuni nege ɲɛnabɔyɔrɔw la, o bɛ kɛ sababu ye ka banabagatɔw bila ka dumuni dunta dɔgɔya, o la, a bɛ dɛmɛ don ka u farikolo girinya dɔgɔya. A bɛ kɔnɔbara lankolonya fana bila kɔfɛ, dumuni to kɔnɔbara la waati janya ani ka don banakɔtaa fitini kɔnɔ dɔɔni dɔɔni, o bɛ joli sukaro hakɛ caya teliya bali^ka .

Jaa 1 ka baara kɛcogo T irzepatide ^{[6] .}.

kɛcogo ye mun ye T irzepatide (T irzepatide) ?

Farikoloɲɛnajɛ suguya 2 furakɛli: 

Tirizepatidi dagalen don ka banabagatɔ balikuw furakɛ minnu farikolojɔli dumuni suguya 2 bɛ u la, o ye dumuni ni farikoloɲɛnajɛ dɛmɛnan ye. SURPASS ka sɛgɛsɛgɛli y’a jira ko Tirzepatide bɛ dɔ bɔ kosɛbɛ ɛmoɲini A1c (HbA1c) hakɛ la, ni a dɔgɔyali bɛ daminɛ -1,87% na ka se -2,59% ma (-20 fo -28 mmol/mol). A bɛ sukarodunbana kunbɛncogo ɲuman fana jira ni a bɛ tali kɛ GLP-1 minɛbaga agoniste dɔw la, i n’a fɔ semaglutide miligaramu 1 SUPRASS-2 sɛgɛsɛgɛli la. Ka fara o kan, a bɛ se ka farikolo girinya dɔgɔya, ni girinya bɛ bɔ kilogaramu -6,2 la ka se kilogaramu -12,9 ma kɛnɛyaso ka sɛgɛsɛgɛliw la, o nafa ka bon kɛrɛnkɛrɛnnenya la banabagatɔw ma minnu farikolojidɛsɛ suguya 2 bɛ u la, minnu ka teli ka girinya kojugu walima fasa koɲɛw sɔrɔ ^[1,.

Fasa furakɛli: 

Ikomi Tirzepatide bɛ fasa sabati, ka dumuni dunta dɔgɔya, ani ka farikolo girinya dɔgɔya, a bɛ se ka kɛ furakɛli nafa ye banabagatɔw ma minnu fasalen don. Kɔlɔsiliw y’a jira ko a bɛ se ka dɔ bɔ mɔgɔ girinya la ni 20% ni kɔ ye, ka banabagatɔw ka farikoloɲɛnajɛ kɛcogo ɲɛ, ka kɛ fura kura ye fasa la, ka banabagatɔ fasalenw dɛmɛ u ka girinya dɔgɔya ani ka dɔ bɔ bana suguya caman na minnu bɛ sɔrɔ fasa fɛ ^[1,.

Dusukun ni jolisiraw ka banaw farati bɛ dɔgɔya: 

Banabagatɔ minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, a ka ca a la, dusukun ni jolisiraw ka banaw ka teli ka caya. Ka fara sukaro ni girinya dɔgɔyali kan, Tirzepatide bɛ nɔ ɲuman bila dusukun ni jolisiraw taamasiɲɛw la, i n’a fɔ tansiyɔn dɔgɔyali, ka farikolo tulu dalajɛli dɔgɔya, ani ka triglycéride hakɛ dɔgɔya farikolo la, o la, a bɛ dɛmɛ ka dusukunnabana farati dɔgɔya ani ka banabagatɔw ka dusukun ni jolisiraw kɔlɔlɔw ^ɲɛ.

Furakɛli min bɛ se ka kɛ sɔgɔsɔgɔninjɛ min tɛ dɔlɔ ye (NASH): 

Tirzepatidi bɛ se ka furakɛli kɛ NASH la. Ni a bɛ inisɔndiya kɛcogo ɲɛ ani ka sukaro ni tulumafɛnw sɛnɛcogo ɲɛnabɔ, a bɛ se ka sugunɛbilenni ni funu dɔgɔya, o bɛ sira kura di NASH furakɛli ^ma.

Kuncɛli

I n’a fɔ GIP/GLP-1 dual receptor agoniste, Tirzepatide ye nafa caman jira farikoloɲɛnajɛ ni farikoloɲɛnajɛ banaw furakɛli la. Ni a bɛ inisɔndiya ni sukaro bɔli ɲɛnabɔ, ka kɔnɔbara lankolonya bila kɔfɛ, ani ka fasa bonya, a bɛ ɛmoɲini A1c hakɛ dɔgɔya kosɛbɛ ani ka banabagatɔ girinya dɔgɔya. Ka fara o kan, fura in bɛ dusukun ni jolisiraw ka faratiw ɲɛ i n’a fɔ tulumafɛnw hakɛ ani tansiyɔn ani ka a jira ko a bɛ se ka kɛ sugunɛbilenni na min tɛ dɔlɔ ye.

A sɛbɛnbaga ko la

Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.

Dɔnniya gafe sɛbɛnbaga

De Block C bɛ jɛ ni Anvers Iniwɛrisite n’a ni a ɲɔgɔnna baaradaw ye Bɛliziki, i n’a fɔ Inflamed Ctr Excellence, Iniwɛrisite dɔgɔtɔrɔso Anvers (UZA ani Univ Hosp Anvers), ani Infla Med Ctr Excellence. A ka ɲininiw bɛ dakun caman na, i n’a fɔ Endocrinology & Diabetes, a bɛ sinsin yɔrɔ min na ɔrimɔni ni farikoloɲɛnajɛ banaw kan; Gastroenterology & Hepatology, ka dumunikɛcogo ni sugunɛbanaw sɛgɛsɛgɛ; General & Internal Medicine, min bɛ kɔnɔnabana caman sɛgɛsɛgɛli n’u furakɛcogo ɲɛfɔ; Nutrition & Dietetics, ka balocogo sɛgɛsɛgɛ ani a nɔfɛkow kɛnɛyako la; ani Urology & Nephrology, olu bɛ sugunɛ ni sugunɛbanaw banaw ni u furakɛcogo sɛgɛsɛgɛ. Ale ye dɔnnikɛla ye min ka dɛmɛba bɛ furakɛli baara caman na. De Block C bɛ sɔrɔ citation (citation) ɲɛfɔli sɛbɛn kɔnɔ [4].

▎ Sɛbɛn minnu bɛ tali kɛ o la

[1] Wong E, Cope R, Dima L, ani mɔgɔ wɛrɛw. Tirzepatide : Insulinotropic Polypeptide Dual Glucose-dependent ani Glucagon-like Peptide-1 Agonist ye sukarodunbana suguya 2 furakɛli kama[J]. Ameriki ka furakɛli gafe, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, ani a ɲɔgɔnnaw. Tirizepatidi, sukarodunbana ni fasa furakɛli laɲini fila kan[J]. Duniya kɔnɔ, ɲinini kura ni yiriwali gafe, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, ani a ɲɔgɔnnaw. Tirzepatide ye sukarodunbana kɛlɛli molekiyɔrɔ kura ye min bɛ wale fila jira[J]. Foroba kɛnɛya sɔrɔ, 2024,21(1):75.DOI:10.1186/s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, ani a ɲɔgɔnnaw. Tirzepatidi min bɛ kɛ ka balikuw furakɛ minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la: Endocrine perspective[J]. Jabɛti Fasa & Jabɛti, 2023,25(1):3-17.DOI:10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, ani a ɲɔgɔnnaw. Fɛnɲɛnɛmafagalanw ladonni jiginni : Tirzepatide seko jirali sukarodunbana kunbɛnni na ani a kɔfɛ[J]. Dɔgɔtɔrɔso furakɛli dɔnnikɛlaw ka seginkanni, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, ani mɔgɔ wɛrɛw. K’a ta glycocentric fɛɛrɛ la banabagatɔ la min ka farikoloɲɛnajɛ suguya 2 bɛ a la ka taa a bila farikolo yɔrɔ caman kunbɛnni furakɛli la ani ka dɔ bɔ neuro-nephro-cardiovascular kɔlɔlɔw la.[M]//2023.DOI: 10.5772/intechopen.1002363.

BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, U BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.  

Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *in glass*, o kɔrɔ ye gilasi minɛnw na) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.